EZH2 silencing in tumor-associated endothelial cells led to inhibition of vasohibin1 reactivation-mediated angiogenesis and OC growth in a previous study by Lu et al. [231], supporting the potential of targeting EZH2 as an effective therapeutic approach. The gene discussed is EZH2; the disease is neoplasm.